SCHEMBL1480170

SCHEMBL1480170

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1cc(-c2ccc(OCc3ccc(C(=O)OC)cc3)cc2)ccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
NLRP3 Q96P20 2/20 0.41
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
LMNA P02545 1/20 0.39
SMPD1 P17405 1/20 0.38
MAPT P10636 3/20 0.38
CNR1 P21554 2/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480168 1.00 NPC1 (0.41) NPC1RAB9ANLRP3PSEN1PSEN2
SCHEMBL1480300 0.94 EGLN1 (0.41) NPC1RAB9ANLRP3PSEN1PSEN2
SCHEMBL1480302 0.94 EGLN1 (0.41) NPC1RAB9ANLRP3PSEN1PSEN2
SCHEMBL1480758 0.94 MRGPRX4 (0.42) NPC1RAB9APOLBSMN1; SMN2MRGPRX4
SCHEMBL1480759 0.94 MRGPRX4 (0.42) NPC1RAB9APOLBSMN1; SMN2MRGPRX4
SCHEMBL1481007 0.92 CNR1 (0.41) NPC1RAB9ANLRP3PSEN1PSEN2
SCHEMBL1481005 0.92 CNR1 (0.41) NPC1RAB9ANLRP3PSEN1PSEN2
SCHEMBL1481371 0.91 NLRP3 (0.43) NLRP3MAPTCNR1POLB
SCHEMBL1481372 0.91 NLRP3 (0.43) NLRP3MAPTCNR1POLB
SCHEMBL1481151 0.90 CNR1 (0.41) NPC1RAB9ANLRP3PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ NPC1 3792/4885RAB9A 3266/4885NLRP3 1828/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ NPC1 3792/4885RAB9A 3266/4885NLRP3 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.